证券之星消息，截至2026年1月30日收盘，美好医疗(301363)报收于31.06元，下跌1.52%，换手率 2.68%，成交量10.02万手，成交额3.11亿元。 | 指标 | 美好医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 176.69亿元 | 111.02亿元 | 16 127 | | 净资产 | 37.02亿元 | 38.45亿元 | 41 127 | | 净利润 | 2.08亿元 | 2.1亿元 | 27 127 | | 市盈率(动) | 63.65 | 104.17 | 62 127 | | 市净率 | 4.83 | 4.04 | 100 127 | | 毛利率 | 39.34% | 50.94% | 89 127 | | 净利率 | 17.43% | 9.66% | 43 127 | | ROE | 5.79% | 0.43% | 46 127 | 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85% ...

近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 证券之星消息，截至2026年1月29日收盘，美好医疗(301363)报收于31.54元，上涨0.38%，换手率 5.84%，成交量21.81万手，成交额7.12亿元。 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：医疗器械精密组件及产品的设计开发、制造和销售,为全球医 疗器械企业提供从产品研发到批量交付的全流程一站式服务。 1月29日的资金流向数据方面，主力资金净流入3686.46万元，占总成交额5.18%，游资资金净流出 1350.46万元，占总成交额1.9%，散户资金净流出2336.01万元，占总成 ...

近5日资金流向一览见下表： 美好医疗融资融券信息显示，融资方面，当日融资买入4868.64万元，融资偿还5884.57万元，融资净偿 还1015.93万元。融券方面，融券卖出2400.0股，融券偿还1800.0股，融券余量5.08万股，融券余额 163.41万元。融资融券余额3.21亿元。 近5日融资融券数据一览见下表： 该股主要指标及行业内排名如下： 证券之星消息，截至2026年1月26日收盘，美好医疗(301363)报收于32.18元，下跌5.46%，换手率 4.83%，成交量18.03万手，成交额5.96亿元。 1月26日的资金流向数据方面，主力资金净流出7406.67万元，占总成交额12.43%，游资资金净流出 1831.57万元，占总成交额3.07%，散户资金净流入9238.24万元，占总成交额15.5%。 该股最近90天内共有7家机构给出评级，买入评级7家；过去90天内机构目标均价为24.57。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量 ...

美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：医疗器械精密组件及产品的设计开发、制造和销售,为全球医 疗器械企业提供从产品研发到批量交付的全流程一站式服务。 该股最近90天内共有8家机构给出评级，买入评级8家；过去90天内机构目标均价为24.57。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成 ...

证券之星消息，截至2026年1月21日收盘，美好医疗(301363)报收于32.58元，上涨0.8%，换手率 4.35%，成交量16.22万手，成交额5.3亿元。 该股主要指标及行业内排名如下： 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：医疗器械精密组件及产品的设计开发、制造和销售,为全球医 疗器械企业提供从产品研发到批量交付的全流程一站式服务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股最近90天内共有8家机构给出评级，买入评级8家；过去90天内机构目标均价为24.57 ...

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Meihao Medical (301363), including stock price movements and funding flows [1][2]. - As of January 19, 2026, Meihao Medical's stock closed at 32.45 yuan, experiencing a decline of 0.76% with a turnover rate of 3.74% and a trading volume of 139,500 hands, resulting in a transaction amount of 455 million yuan [1]. - In terms of funding flow on January 19, 2026, the main funds saw a net outflow of 3.97 million yuan, accounting for 0.87% of the total transaction amount, while retail investors experienced a net outflow of 1.89 million yuan, representing 4.14% of the total transaction amount [1]. Group 2 - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, reflecting a year-on-year increase of 3.28%, while the net profit attributable to shareholders decreased by 19.25% to 208 million yuan [2]. - The third quarter of 2025 showed a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit attributable to shareholders of 93.90 million yuan, which is a 5.89% increase year-on-year [2]. - The company has a debt ratio of 11.43%, with investment income of 4.90 million yuan and financial expenses of -27.39 million yuan, alongside a gross profit margin of 39.34% [2].

Core Viewpoint - Meihua Medical reported a significant enhancement in profitability for the third quarter of 2025, with a year-on-year revenue increase and a proposed cash dividend distribution to shareholders [1] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 1.194 billion yuan, representing a year-on-year growth of 3.28% [1] - The net profit for the same period was 208 million yuan [1] - In the third quarter alone, revenue reached 462 million yuan, marking a year-on-year increase of 2.56% [1] - The net profit for the third quarter was 93.9 million yuan, reflecting a year-on-year growth of 5.89% [1] Profit Distribution Plan - The company announced a profit distribution plan based on a total share capital of 569 million shares, proposing a cash dividend of 0.80 yuan for every 10 shares, totaling 45.42 million yuan (including tax) [1] - This distribution is aligned with the company's development stage and profitability, aiming to share operational results with shareholders [1] Business Strategy - Meihua Medical focuses on the design, manufacturing, and sales of precision components and products in the medical device sector, providing a comprehensive one-stop service [1] - The company aims to become a leading global medical technology service provider [1] - The growth in the medical device and CDMO industry is seen as a favorable external condition for business expansion [1] - A diversified business layout is identified as a long-term growth driver [1] - The company plans to expand its market focus on leading medical device enterprises in Europe and the United States, as well as localizing operations in China [1] - Collaborations with domestic and innovative high-tech medical enterprises are also highlighted as key future business priorities [1]